Search clinical trials for: BI 1181181, T2

Total 1289 results

Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181

Healthy

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI 1181181 in Healthy Male Volunteers

Healthy

Belgium
Boehringer Ingelheim

Terminated

Multiple Rising Dose of BI 1181181 Given Orally in Young Healthy Male and Elderly Healthy Male/Female Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men That Tests if Taking BI 1265162 by Mouth, Intravenously, or Inhaled Influences the Amount of BI 1265162 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy People to Measure the Amount of BI 655130 in the Blood After Injecting Different Doses Into Different Parts of the Body

Healthy

Belgium
Bryan Allen
National Cancer Institute (NCI); Holden Comprehensive Cancer Center

Recruiting

T2* MRI Analysis for Sarcoma

Sarcoma | Magnetic Resonance Imaging | Radiotherapy

United States
Columbia University
University of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaborators

Recruiting

Dynamically Tailored Behavioral Interventions in Diabetes

Type 2 Diabetes

United States
Insud Pharma

Completed

Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil)

Helminthiasis
The University of Queensland

Recruiting

New Diagnostics in Neutropenia

Febrile Neutropenia

Australia
Central Hospital, Nancy, France

Completed

Detection of Acute Graft Rejection in Heart Transplant Patients by Estimation of T2 (DRAGET)

Heart Transplantation | Acute Graft Rejection

France
Association de Recherche Bibliographique pour les...
Centre Hospitalier Universitaire de Nice; Centre Hospitalier Princesse Grace

Completed

Eye Movements Recording Using a Smartphone: Comparison to Standard Video-oculography in Patients With Multiple Sclerosis

Multiple Sclerosis

Monaco
Guangdong Provincial People's Hospital
Chinese Academy of Sciences; Guangdong Zhaotai InVivo Biomedicine Co. Ltd.

Unknown

Phase I Study of CD19-CAR-T2 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Acute Leukemia

Acute Leukemia

China
University Hospital, Lille

Completed

MRI Perfusion on T1 and T2 Brain Lesion(s) (METAPERF)

Lung Carcinoma Metastatic to the Brain

France
Nanfang Hospital of Southern Medical University

Recruiting

CD19-CAR-T2 Cells for CD19 Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Adult | Acute Lymphoblastic Leukemia Not Having Achieved Remission

China
Stryker Trauma GmbH

Completed

A Post-Market Clinical Evaluation of the Treatment of Tibia Fractures With the T2 Alpha Tibia Nailing System

Tibial Fractures

United States
Duke University
National Institute of Allergy and Infectious Diseases (NIAID)

Recruiting

Pneumonia Direct Pilot (PDP)

Pneumonia, Bacterial | Ventilator Associated Pneumonia

United States
Neurocrine Biosciences
Takeda

Completed

A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy Participants

Healthy Volunteers

United States
Memorial Sloan Kettering Cancer Center
Takeda

Active, not recruiting

19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers

Waldenstrom Macroglobulinemia | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma | Burkitt's Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Indolent Non-Hodgkin Lymphoma | Primary CNS Lymphoma | Transformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma

United States
Memorial Sloan Kettering Cancer Center
Takeda

Recruiting

Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma

B-Cell Lymphoma | Large B-cell Lymphoma | DLBCL, Nos Genetic Subtypes | Mediastinal Large B-cell Lymphoma | High-grade B Cell Lymphoma

United States
Istituto Ortopedico Rizzoli

Withdrawn

Diagnostic Performance of 3T MRI T2 Mapping Technique in Chondro-labral Pathology of the Hip, Correlated With Intraoperative Arthroscopic Findings: Interventional Diagnostic Technique Validation Study (HPI MRI 3T)

Hip Arthrosis | Hip Injuries and Disorders

Italy
Daewon Pharmaceutical Co., Ltd.

Completed

A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809-T2

Osteoarthritis | Rheumatoid Arthritis | Back Pain | Acute Upper Respiratory Tract Infection

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Clinical Study to Evauate the Pharmacokinetic Profiles and Safety of CKD-348 in Healthy Volunteers

Healthy

Korea, Republic of
Institut Paoli-Calmettes

Terminated

Adaptated Physical Activity During Chemotherapy: Evaluation of the Psychological, Physiological and Biological Impact (APA2)

Cancer
Eli Lilly and Company

Completed

A Study of LY3337641 in Healthy Participants

Healthy

Singapore
Fondation Ophtalmologique Adolphe de Rothschild

Completed

Prevalence of a High-intensity Signal of the Oculomotor Nerve on T2 MRI Sequence in Patients With Ophthalmoplegia (HYPER-III)

Ophthalmoplegia

France
University Hospital, Bonn
Philips Healthcare

Completed

Deep Learning Super Resolution Reconstruction for Fast and Motion Robust T2-weighted Prostate MRI

Prostate Cancer | Multiparametric MRI

Germany
Chang Gung Memorial Hospital

Completed

Evaluation of Myocardial Iron Deposition in Patients of Heart Failure Using T2* MR Imaging (CHFIRONMR)

Heart Failure | Iron Overload | Cardiomyopathies

Taiwan
Neurocrine Biosciences
Takeda

Completed

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants

Healthy

United States
Shanghai 6th People's Hospital

Completed

Paravertebral Block for Proximal Humeral Fracture Surgery

Proximal Humeral Fracture

China
Dong-A ST Co., Ltd.

Not yet recruiting

Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

Type 2 Diabetes

Korea, Republic of
Karolinska Institutet
Merck Sharp & Dohme LLC

Enrolling by invitation

Education, Immigration and HPV Vaccination: an Informational Randomized Trial

Cervical Cancer | Vulvar Cancer | Head Cancer | Neck Cancer | Genital Wart | Anus Cancer | Penis Cancer | Mouse Papilloma

Sweden
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test if Taking Different Formulations of BI 1358894 With or Without Food Influences the Amount of BI 1358894 in the Blood

Healthy

Germany
Smith & Nephew, Inc.

Terminated

Knee Articular Cartilage Debridement in Conjunction With Partial Meniscectomy (MILE)

Torn Meniscus

United States
Boehringer Ingelheim

Recruiting

A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

Melanoma | Non-small Cell Lung Cancer (NSCLC) | Carcinoma, Squamous Cell of Head and Neck (HNSCC)

Netherlands
HaEmek Medical Center, Israel
Wolfson Medical Center

Completed

Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia

MRI | Iron Overload | Sickle Cell Anemia | Sickle Cell Thalassemia

Israel
Boehringer Ingelheim

Not yet recruiting

A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity

Obesity
Boehringer Ingelheim

Completed

This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Looks at How Food Influences the Amount of BI 1358894 in the Blood

Healthy

Germany
Weill Medical College of Cornell University
Novartis Pharmaceuticals

Completed

MRI Screening for Patients With Myelodysplastic Syndrome (MDS), Who Have Received Multiple Red Blood Cell Transfusions (T2*MRI)

Myelodysplastic Syndrome (MDS)

United States
Boehringer Ingelheim

Withdrawn

A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer

Anal Canal Squamous Cell Carcinoma

Korea, Republic of
Boehringer Ingelheim

Recruiting

A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body

Solid Tumors

Hungary
Boehringer Ingelheim

Terminated

A Study in Healthy Men to Find the Best Formulation of BI 894416 and to Test How This is Taken up in the Body

Healthy

United Kingdom
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1015550 is Taken up and Handled by the Body

Healthy

Netherlands
University of Illinois at Chicago
National Institute of Nursing Research (NINR); Kamuzu College of Nursing, University...

Completed

A Community-based Implementation Model for HIV Prevention and Testing in Malawi

HIV CDC Category A1

Malawi
Nottingham University Hospitals NHS Trust

Unknown

DiagnosE Using the Central veIn SIgn (DECISIve)

Multiple Sclerosis

United Kingdom
St. Jude Children's Research Hospital

Completed

Pilot Study of Non-Invasive Assessment of Hepatic And Myocardial Iron Through T2* Magnet Resonance Imaging (MRI) In Patients With Iron Overload

Hematological Diseases

United States
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 in Otherwise Healthy Controlled Asthmatic Subjects

Healthy | Asthma

Germany
Boehringer Ingelheim

Completed

Single Rising Dose Study With Intravenous Infusion and Subcutaneous Injection of BI 1005273 in Healthy Male Volunteers.

Healthy

Germany
Boehringer Ingelheim

Completed

This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.

Neoplasms | Carcinoma, Non-Small-Cell Lung

United States, Spain, United Kingdom, Canada, Poland
Boehringer Ingelheim

Terminated

A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread

Neoplasms | Carcinoma, Non-Small-Cell Lung | Neoplasm Metastasis

United States

3

Subscribe